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•ABSTRACT'

It

is

well

known

that

many

plants,

algae,

and

microorganisms contain or secrete agents which may exhibit

anti-cancer, or cell growth modulating properties/ :: Qf

these', extracts from Chara alobularis Thui11. a fresh
water alga, may contain an agent(s) which exhibits such
properties.

Experiments were designed to address the

question> does the potential growth inhibitory properties
of Chara. alter specific nuclear growth indicators in
cancerous and non-cancerous cells, and if so what might

this indicate

about the potential mechanism of

Chara

extract?

From this question, the hypothesis that Chara

modulates

the appearance of nuclear growth indicators

related to transcription and cell-cycle in Jensen sarcoma
but

not

in

non-cancerous

cells

was

derived.

In

this

study, the effects of Chara extracts were compared to a

well characterized anti-neoplastic agent, doxorubicin.
The cancerous cell line, Jensen sarcoma, which has
been shown sensitive to treatment with extract from Chara

both in vivo and in vitro, was
cancerous

cell

lines,

Intestine 407 cells.

Chang

compared

liver

The effects

and

of Chara

to

the non

(embryonic)
extract and

doxorubicin on cells were assessed by immunefluorescence
using antibodies that recognize

the following nuclear

proteins: fibrillarin, p-80 coilin, and proliferation cell

nuclear antigen (PCNA).

Fibrillarin, a nucleolar protein

associated with U3 small nuclear ribonucleoprotein (snRNP)

and involved in rRNA processing, may provide information
on the integrity of nucleolar processes.

P80-coilin is a

unique protein that is associated with nuclear structures
referred to as coiled bodies.

Coiled bodies (CBs) are

most prominent in hormonally Stimulated tissues and cancer
cells.

Their frequency has been correlated with high

111

receptor levels and enhanced transcription in several

steroid-hormone tarqet tissues.

PCNA is a cell-circle

dependent protein, associated with DNA polymerase delta.
During

DNA replication, PCNA becomes associated with

replication
pattern.

sites

and

exhibits

a

granular

labeling

Using these antibodies, information about the

action of the anti-neoplastic agents on transcriptional
and cell-cycle processes were monitored.
Jensen

sarcoma

with

5%

v/v

Chara

Treatment of

extract

or

5nM

doxorubicin for 6 days was sufficient to alter the rate of
growth and reduce cell density by 50%.

Similarly, the

rate of growth and cellular density of Intestine 407 cells
appeared to lowered by treatment with doxorubicin.

In

contrast, Chara extract did not alter the rate of growth

of either Chang liver or Intestine 407, but did depress

cell density near the plateau phase.
Although neither Chara extract or doxorubicin seemed

to

greatly

fibrillarin,

affect

major

nuclear

structures

differences

were

containing

apparent

in

CB

frequency with respect to cell type, time, and treatment.

In Jensen sarcoma, coiled body frequency was sharply
decreased after treatment with either agent, relative to
control cells.

Chara extract did depress the CB frequency

in the non-cancerous cells as well, but this effect was
less

dramatic

than

observed

in

Jensen

sarcoma.

Additionally, the effect Chara extract on CB frequency was
less, compared to doxorubicin treated intestine 407 cells.

Assessment

Of cell-cycle

against PCNA

showed

parameters

using

that Jensen sarcoma

antibodies

treated

with

either Chara extract or doxorubicin exhibited significant

changes in the PCNA labeling distribution compared to
controls.

These changes were more dramatic in Chara

extract treated Jensen sarcoma compared to doxorubicin.
Although, non-cancerous cells treated with either agent

IV

did

exhibit some

changes,

these

dramatiG as seen in Jensen sarcoma.

effects

were

not as

Goilectively, these

observations revealed a complex pattern of change in
nuclear

transcriptional

and cell-cycle

activitY

respect to time, cell type and treatment.

with

Additionally,

these observations suggests that Chara exitract does appear
to Contain agent(s) which exhibit a selective cytostatic
activity against JensCn sarcoma compared
cancerous cells.
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INTRODUCTION

,

In the continuing search for new drugs which exhibit
anti^cancer and cell growth inhibitory properties, interest

has increasingly focused on natural products-

Extensive

studies along these lines have resulted in the discovery of
several natural compounds with promising potential,
Review:

(For

Slichenmyer and Von Hoff, 1990). Among these, Taxol,

isolated from Western yew bank, has received much attention
recently and is undergoing extensive clinical testing.

Fresh

water algae from the genus Chara may also contain agents with

cancer growth inhibitory properties.

What follows is a

review of Chara's biological properties in terms of cell
growth inhibition, as well as a review of literature related
to this project as a whole.

Biological Properties of Chara

Caballero (1919) first reported on potential

mosquitocidal properties of Chara after observing the absence
of larvae in waters where the algae bloomed.

These

observations were subsequently confirmed and extended by
other investigators (Vasconcelos, 1923; Buhot, 1927)

More

recently, the potential use of Chara in mosquito control was

investigated by Amonkar (1969). By utilizing organic extracts
from Chara. Amonkar reported iirpaired mosquito larval

development. Utilizing oospores from Chara in nutrient agar,

Harrington (1969) showed that the growth of various types of
bacteria could also be inhibited.

The broad base inhibitory

action of Chara isolates was further demonstrated by WiumAndersen et al. (1982)

They showed that two sulfur

compounds isolated from C. alobularis exhibited allelopathic
effects on phytoplankton by inhibiting photosynthesis in the

diatom Nitzschia palea.

These inhibitory effects have also

been extended to mammalian systems.

Su and Staba (1973)

reported the growth of amelanoma tumors was delayed in

hamsters following intramuscular injection of organic
extracts from Chara vulaaris.

Similarly, Sherif (1980)

observed remission of polyoma tumors in rats after a single
intratumor injection of steam distillates from Chara

globularis.

He also reported an increase in agglutination of

polyoma transformed, embryonic rat heart Cells, following

treatment with Chara.

More recently, studies by Gallo

(personal communication) showed that steam distillates from

Chara globularis were capable of inhibiting the growth of
Jensen sarcoma tiomors in Sprague-Dawley rats following

intratumor injection.

Along similar lines, Inman (1986),

utilizing organic extracts from steam distillates from Chara
globularis, observed a delay in growth of Jensen sarcoma and

rat kidney cells in vitro.

Additional studies by Gallo also

showed that such distillates were able to retard the growth
of several neoplastic cell lines in vitro, including Jensen
sarcoma, hioman pancreas epithelioid carcinoma, and human
glioblastoma.

In contrast, similar treatment of noinnal human

lung cells had no apparent growth retardation or toxic side
effects.

It is unlikely that the observed anti-neoplastic action
of Chara extracts is primarily attributable to toxic side
effects.

In vivo studies with rats (Sherif, 1980) and mice

(Gallo, personal communication) have indicated that steam
distillates from Chara globularis are non-toxic to these

animals.

For example, distillates given to mice as a

substitute for water for a period of three months resulted in
no animal deaths attributable to the extract.

Su and Staba

(1973) assessed possible coagulant or anticoagulant
properties of an organic extract from Chara vulgaris.

They reported no changes in prothroinbin time or partial

thromboplastin time following intraperitbneal injections of
mice with the extract.

Only limited information is available on the identity of
compoxxnds present in extracts from Chara alobularis
(Harrington and Gallo, 1985; Anthoni et al., 1980)

Two

classes of agents present in the mixture, undecanal and

various sulfur drugs are known to have anti-neoplastic

activities (Higaashikaze, 1981).

Undecanal compouhds have

been shown to exhibit anti-neoplastic activities in SV40
virus-induced tumors in mice (Higashikaze, 1981), while
sulfur compounds reportedly exhibit anti-neoplastic
activities in vivo and in vitro (Bourgougnon et al., 1994;
Hensel, 1995)

Functional Organization of the Cell Nucleus

In an effort to better docviment the potential
anti-neoplastic properties of Chara. the present

investigation placed particular eitphasis on large-scale
nuclear changes in cells exposed to extracts from this alga.
What follows is a review of the major structural and

functional aspect of nuclear organization.

A. Overview of Nuclear Organization

Structurally the interphase nucleus can be divided into

several domains with specific functions (For Review: De Jong
et al., 1996; Spector, 1993; Brasch and Ochs 1992) which are

shown in figure 1.

The most prominent nuclear domains

include the nuclear envelope, chromatin, nucleoli, and the
interchromatin space.

The nuclear envelope helps to

segregate, both terrporally and spatially, major nuclear

processes from those in the cytoplasm.

Figure 1.

Diagram illustrating the major components of a

maiiimaliah interphase nucleus.

The nucleus is separated from

the cytoplasm by a nuclear envelope (NE), through which
proteins and nuclear transcripts are exported and/or imported
via nuclear pores (NP). The most prominent structure in the
nucleus is the nucleolus (Nuc) where rRNA genes are located
and is the site for rRNA transcription. Condensed chromatin
(Ch) is located primarily on the internal periphery of the
nucleus, with transcribed or potentially transcribed
chromatin looped internally. An array of structures can be
found within the interchromatin domain, including

perichrornatin granules (PG) and fibrils (PF), as well as
interchromatin granules (IG), small nuclear bodies (SNB) and
coiled bodies (CB).

(J1

v.*.'
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The flow of molecules between the nucleus arid the cytoplasm
is regulated via nuclear envelope pores.

For example,

ribosomal subunits and mRNA molecules must exit this way
before coming together in the cytoplasm for protein
synthesis. The pores also regulate the entrance of proteins
and other molecules into the nucleus for structural purposes
and to modulate gene expression and related functions.

Chromatin can be grouped into two distinct domains,

euchromatin and heterochromatin.

Euchromatin represents

chromosomal regions which extend into the interchromatin

space and contains genes which are being, or are ready to be,
transcribed. Heterochromatin or condensed chromatin

represents regions not poised for transcription at that point
in time, as well as telomeric and centromeric regions that
are linked to the nuclear envelope.

All chromosomal regions,

however, decondense at some point in time during S-phase when
they replicate.

The nucleolus usually appears as a dominant, condensed

structure within the nucleus during interphase. This
structure can be divided into three main elements:

fibrillar

centers, dense fibrillar coitponent, and the granular
component.

The nucleolus is composed of various proteins,

like fibrillarin, silver staining nucleolar organizing
regions and specific chromosomal regions containing several
tandem repeats of genes (rDNA) coding for ribosomal RNA
(rRNA).

The interchromatin space is pervaded by an

interconnected network of proteins and other macromolecules

that may constitute a scaffold or matrix for transcription

and replication.

Some of these components include

interchromatin granules, which are small nuclear

ribonucleoprotein (snRNP) clusters, and perichromatin
granules and fibrils which are usually located at the

periphery of chromatin, and which constitute newly

transcribed pre-mRNA coinplexes.

.

Lastly, this nuclear region also contains prominent
structures collectively termed nuclear bodies.

Nuclear

bodies contain a number of well defined molecular components
(see below) whose collective functions in these structures
remain unclear (For Review:

Lamond and Carmo-Fonseca, 1993;

Brasch and Ochs, 1992).

B. Nuclear Bodies and Coiled Bodies

Nuclear bodies were first observed by Cajal (1903) in
neuronal cells after silver inpregnation.

He referred to

them as "accessory bodies" due to their proximity to
nucleoli.

Although several different morphotypes were later

described through electron microscopy (Bouteille et ali,
1982), as a group these structures appear highly conserved in

evolution, being found in both plants and animals (Moreno
Diaz de la Espina et al., 1982; Raska et al., 1991).Nuclear

bodies of all types seem most prevalent in hyperactive cells
such as cancerous tissues (Bouteille et al.,1982), virally
transformed cells (Jiang et al.,1991) lectin-stimulated

lymphocytes (Chaly et al., 1983), and hormonally stimulated

tissues (Vagner-Gapodano et al., 1982; Brasch and
Peters,1985; and Brasch et al., 1989).

Stimulation of such

tissues generally induces an increase in the nxiiriber of

nuclear bodies, while absence of stimulation is followed by a
decline in frequency.
Recently the designation "coiled bodies" (CBs) has been
used to describe the best characterized subclass of nuclear

bodies (For Review: Brasch and Ochs 1992; Lamond and Carmo

Fonseca, 1993).

The formation

of CBs appear to come about

through nucleolar budding (Dupuy-Coiln and Bouteille, 1972;
Vagner-Capodano et al., 1980; Raska et al., 1990), with some

CBs being identified within the nucleolus of some cell lines
(Ochs et al., 1994).

The molecular composition of CBs was largely unknown

until the discovery of autoantibodies that specifically react
with nuclear antigens (For Review: Raska et al, 1991).

It is

now known that CBs contain several specific molecular

components.

P80-coilin is an 80Kd molecular weight protein

which is prevalent in all coiled body-like structures so far
examined (Andrade et al., 1991).

The antigen appears in two

states, an insoluble sta:te, which forms CBs and a soluble

State, which exists both in the nucleus and the cytoplasm.

This distribution appears to be cell-cycle dependent (Andrade
et al., 1993), and is possibly regulated by
hyperphosphorylation of p80-coilin during mitosis (CarmoFonseca et al., 1993).

The presence of fibrillarin and silver staining
nucleolar organizer proteins in both nucleoli and CBs
suggests a functional relationship may exist between these

two structures (Raska et al.,1990).

Fibrillarin is a 34 KD

nucleolar protein, associated with U3 snRNP and fibrillar
regions of the nucleolus, which has been identified in some
CBs but not all (Ochs et al, 1985; and Ochs and Smetana

1991).

The association of fibrillarin with CBs appears to be

greater in non-cycling cells relative to cycling cells (Raska
et al., 1990).

Another group of important proteins detected in CBs are
those associated with pre-mRNA splicing processes, called
snRNP's (Raska et al., 1991; Lamond and Carmo-Fonesca, 1993).

They are ubii^itous in active cell nuclei and usually appear
clustered in interchromatin granules and perichromatin
fibrils (Fakan et al., 1984).

Differences in snRNP

distribution in nuclei from primary cell lines and
immortalized cells have been observed (Spector et al., 1992).

Immunofluorescence staining for snRNPVs in primary cell

lines, exhibited a broadly speckled distribution, along with
a small percentage of cell (2-3%) with discrete foci which
colocalized with GBs.

In contrast, immortal REF-52 cells

exhibited a higher percentage (4-40%) of colocalized CB foci,
while adenovirus transformed REF-52 cells exhibited an even

higher percentage.
The above results confirmed and extended the long
standing observation that cancer and transformed cells

contain elevated number of CBs relative to other types of
tissues.

The localization of snRNP's in GBs appears to be

transcription dependent and sensitive to heat shock,

actinbmycin-D, and a-amanitin, which appears to displace
snRNP's from coiled bodies and appears to result in increased

association with fibrillarin (Raska et al., 1990; GarmoFohseCa et al., 1992).

Along with snRNP's, snRNA's have also

been detected in GBs by jji situ hybridization.
In addition to the above cortponents, several other
proteins have been detected in coiled bodies.

These include

DMA topoisomerase I, M3G-capped RNA (Andrade et al, 1991;
Raska et al.,1991) and a protein non-snRNP splicing factor,

U2AF, which is an auxiliairy factor for U2 snRNP (Zamore and
Green, 1991).

It is likely that as more specific antibodies

become available, additional GB-associated components will
also be revealed.

Despite containing nimierous iirportant nuclear proteins,
the precise function of coiled bodies is still unclear
(Brasch and Ochs, 1992). However, the association of GBs with

nucleoli in both cycling and non-cycling cells, suggests that

these bodies may play different functions depending on the
physiological state of the cell (RaSka et al., 1990).

For instance, the presence of various snRNP splicing factors
and other agents involved in RNA processing, and the presence
of fibrillarin and nucleolar organizing regions, iitplies that

9

CBs may play a role in both pre-inRNA processing and/or
nucXeolU.s associated processes.

Regardless of function, it

is clear that GBs are structural indicators of

transcriptional activity in nuclei where they are abundant.

This suggests that CBs might also be used to monitor the
effects of anti-neoplastic agents. "

e. Proliferating Cell Nuclear Antigen (PCNA)

The use of antibodies that detect a 36 Kd nuclear

auxiliary protein for DNA polymerase delta, known as

proliferating cell nuclear antigen (PCNA), can provide
further information on the replicative status of cells and
tissues (Celis et al., 1984; Dietrich, 1993).

PCNA is

synthesized in normally proliferating and transformed cells,
but is present in only very low amounts in quiescent cells.
Like p80-coirin, PCNA also appears to exist in two states, a
soluble nucleoplasmic form and an insoluble form which is
associated with DNA relication sites. Cells entering late G1
and early S-phase exhibit a immuneflucrescence pattern absent

in nucleolar labeling.

As DNA replication proceeds, PCNA

becomes associated with specific nuclear structures and
exhibits a granular labeling pattern which appears to
coincide with DNA replication sites (Bravo and Macdonald-

Bravo, 1987).

Completion of DNA synthesis results in a more

general staining pattern (Bravo and Macdonald-Bravo, 1985;
and Bravo, 1986).

excision repair.

PCNA has also been implicated in DNA

Cells exposed to UV irradiation exhibit

granular labeling which coincides with sites of repair (Celis
and Madison, 1986; Toschi and Bravo, 1988).
Therefore, PCNA may be used as a indicator of the
proliferation status of cells and may provide potential
information on the mechanism of action for anti-neoplastic
agents.

10

METHODS

Project Overview

A. Cell Lines Characterization

All experimehtation for this project was planned using
the cancerous cell line, Jensen sarcoma (passage nvuriber
-100), and two nOn-cancerouS lines, Chang liver (passage
number —300) and (embryonic) Intestine 407 (passage number
-300).

Jensen sarcoma was shown previously to be sensitive

to extracts from Chara. both in vivo and in vitro

above).

(see

The cells exhibit contact inhibition in vitro. and

are attachment dependent, meaning that they require a solid
substrate to undergo cell divisiori (Beltz, 1983).

Chang

liver and Intestine 407 are immortalized cells by way of
continual passage.

It is currently vinknown whether this

immortalization is due to an acciomulation of genetic Changes
in cultures or if variants initially present in the culture
were selected for by serial passage.

B. Doxorubicin

Doxorubicin (Adriarrycin), a well characterized
antibiotic used in treatment of cancers, was chosen as a

comparison agent for the Chara extract.

Doxorubicin is a

broad spectrum antibiotic isolated from a strain of

Streotomvces oeucetius (Acromone et al., 1969).

It works by

intercalation between base pairs in the major groove in DNA
(Zunino et al., 1972).

This intercalation inhibits the

enzymes involved in DNA replication and transcription (Bachur
et al., 1992; Chuang and Chuang, 1979).

Doxorubicin has been

observed to exhibit growth inhibitory activity on Chinese
hamster ovary cells at the microgram level with short

11

exposure times as little as 1 hour (Barranco and Novak,

1974).

With longer exposure ti^es (24 or more hours) effects

have been observed at the nanogram level (Bempong and Brooks,
1977).

C. Experimental Design and Goals

This study examines the overall question, does Chara
extract alter specific nuclear indicators, and if so what

might this indicate about the possible mechanism(s) of
action?

Based off of this question, the hypothesis that

Chara modulates the appearance of nuclear growth indicators
related to transcription and cell-cycle in Jensen sarcoma but
not in non-cancerous cells was derived.

To address this

question, several initial questions were raised and
appropriate experiments developed.

First, does Chara extract

naturally contain possible anti-neoplastic agents?

This

question was addressed by performing dose response curves in
Jensen sarcoma with Chara extract or doxorubicin.

A dose

which produced an approximate 50% reduction in cell numbers
in Jensen sarcoma, as assessed by hemocytometer counts, was

chosen.

The doses enployed in this study were obtained from

dose response curves using various concentrations of Chara
extract or doxorubicin (data not shown).

Based on these

initial studies, 5% v/v Chara extract and 5nM doxorubicin

were chosen.

2% Chara extract or 2.5nM doxorubicin produced

minimal reduction (-10%) in Jensen sarcoma.

A 75% reduction

of cell density was obtained with 10% Chara extract, while

lOnM doxorubicin resulted in no cellular proliferation.

The

other cell lines were exposed to the same concentration of
doxorubicin and/or Chara extract chosen.

Once this was established, the question was raised, does
Chara extract alter specific nuclear indicators related to

transcriptional activity, and how does this effect compare to
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doxorubicin?

This question was addressed through

immunpfluorescence microscopy using antibodies that recognize
p80-coilin and fibrillarin.

Anti-p80-coilin was used to

identify and quantify coiled bodies through fluorescence

microscopy.

Similarly, anti-fibrillarin was used to quantify

nucleoli and small peripheral structures.

Anti-fibrillarin

antibodies were also used to differentiate between

fibrillarin positive and negative labeled CBs.

Since CBs can

serve as indicators of nuclear and nucleolar hyperactivity
(Bouteille et al., 1987; Brasch and Ochs, 1992), changes in
their numbers can be used as broad indicators of both

transcriptiohal levels arid nucleolar function.

These microscopic Studies were accompanied by western
blot quantification of SDS gel^separated cellular proteins to
determine total cellular amounts of p80-coilin.
Finally, the question was asked, does Chara extract

alter the cyCle-cycle, and how does this effect compare to
doxorubicin?

This question was addressed by employing

immunofluoreScenCe microscopy using anti-PGNA antibodies.
The PGNA labeling pattern was used to score the phases of
cell division.

PGNA is a nuclear protein correlated with

proliferation of cells during the S-phase and becomes

associated with replication sites (Bravo and Maconald-Bravo,

1987).. . , ■ ■ ■
This study provides data on the effects of Ghara extract
on the growth of cancerous and both non-cancerous cell lines,

utilizing sCme very specific nuclear cortponents as indicators
and then by coirparing these effects to those of doxorubicin,

a well defined anti-neoplastic agent.

In addition to the

questions' mentioned a,bove, several other questions are

addressed. 1) Does the average number of GBs vary between the
neoplastic cells and the non-cancerous lines, and if so what

might this difference mea.n?

2) What changes occur in GBs in

the three cell lines during proliferation?
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3) If there is a

change, what could this indicate regarding transcriptional

activity in relation to the growth of individual cell lines?
4) If fibrillarin and pSO-coilin reveal two differeht
populations of CBs, is there a change in these populations
during proliferation?

5) Does PCNA, which is an indicator of

cellular proliferation, differ among the three cell lines,

does it vary with respect to the age of the culture, and if
so, what might this indicate?

The cell enumeration data shown in this study was

derived from 3 independent experiments employing 3 separate
batches of Chara extract and doxorubicin to monitor activity
changes between batches.

To control for possible batch

variations, the same batch of Chara extract and doxorubicin
was used in all three cell lines and includes cell

enumeration and all subsequent experiments.

Additionally,

all the experiments for the three cell lines were set up
during the same period.

Due to the variability of these

nuclear indicators in asynchronous cultures, at least a 100
cells from each cell, treatment and time period were
enumerated.

D. Experimental Analysis

All cell growth data, CB, fibrillarin labeled stiructure

covints, and nuclear PCNA pattern quantitation were arranged
in an a x b factorial design and subjected to analysis of
variance (ANOVA)(Milton and Tsokos, 1985; Dowdy and Wearden,
1985) using SuperAnova software (Abacuss).

Data sets

exhibiting significant ihteraction were assessed for the

influence of each factor independently. Pairwise comparisons
were made with treatment (control. Chara and doxorubicin) apd

time (24,48,72,96,120... hrs.) as factors using Duncan's

multiple range test with Kramer's adjustment for unequal
sample sizes (Kramer, 1956).
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Coitpafisons between the cell

types were made within the control groups with cell type
(Jensen sarcoma, Chang liver and Intestine 407) and time as
factors.

To meet the assiamption of homogeneous variances

(homoscedasticity), the sample variances were subjected to
Bartlet's test.

Experiment sets exhibiting significant

hetergenous variances were transformed using the equations
(y=Log e) for cell enumeration and (y=Log e+10) for p80

coilin, fibrillarin enumeration and all data expressed as a
percentage.

Results expressed as significant implies P<0.05

unless otherwise stated.
weighted mean ± SE.

All PCNA data was expressed as

The remaining data was expressed as mean

± SE.

Procedures

A. Cell Cultures

Except where indicated, all basic techniques involving
cell culturing follow general procedures outlined in Freshney
(1983).

Cultures were maintained in media optimized for each

respective cell line as outlined by American Tissue Culture
Collection (ATCC).

Jensen sarcoma cells (ATCC CCL45) were

grown in McCoy's 5A media at pH 7.4 and 5% fetal bovine serum
(FBS).

Chang Liver cells (ATCC CCL13) and Intestine 407

cells (ATCC CCL6) were cultured in Basal modified Eagle's

(BME) media with Earle's salt solution at pH 7.4 with 10%
(FBS) and 15% (FBS) respectively.

All cultures were

supplemented with 1% antibiotic-antimycotic solution

containing 10,000 U/ml penicillin-G, 10,000 |lg/ml
strepton^cin sulphate, and 25 |ig/ml of amphotericin B.
Culture media was buffered with lOmM sodiiam bicarbonate.

All

cultures were maintained in a VWR Scientific model 2100

humidified incubator at 370C with 5% C02 - 95% air flow.

Stock cultures, maintained in 25 cm^ or 75 cm^ flat-bottomed
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polystyrene culture flasks were siobcultured prior to
confluency to maintain cells in log-phase.
To remove cells from the culture flask, they were

treated with 0.25% trypsin and ImM EDTA at 37°C for 5
minutes, followed by addition of fresh media
centrifugation at 2,000g for 5 minutes.

and

Cell pellets were ,

washed in media with FBS and centrifuged again, followed by
resuspension in fresh culture media.

Fresh culture flasks

were then inoculated with cell suspension.

Experimental

cultures were established in similar manner and then allowed

24 hrs to recover from trypsin treatment before exposure to
Chara extracts or doxorubicin (Barranco et al., 1980).

All

cultures were replenished with fresh culture media every 48
hrs following treatment.

All cultures were grown in Corning plates or flasks
except where otherwise indicated.

Culture reagents were

obtained from Gibco Laboratories, Grand Island, N.Y..

Culture manipulations were performed in a Labconco class II
vertical flow hood.

B. Preparation of Anti-neoplastic Agents

Extracts were prepared from the fresh water alga Chara

alobularis Thuillier. grown in a special retaining tank on
the CSUSB canpus.

After harvesting, the material was washed

thoroughly with double-distilled water and then blotted dry.
200-400 grams of

material was then placed in a stainless

steel juice extractor, and 50-80 ml of eluent was collected.

The eluent was sterile filtered (0.2|am acetate filter) and
frozen in 5 ml aliqubts at -80?C.

Doxorubicin-HCij (Sigma)

solution was prepared by suspending lOmg in 10 mL of sterile

filtered double-distilled water (0.2 jam acetate filters).
Aliquots were stored at -80°C.

A 100|lg/ml stock solution was

prepared by serial dilution and stored at 4°C.
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C. Preparation of Culture Media

Culture media was prepared just prior to use in the
following manner.

Thawed Chara extract was sterile filtered

(0.2|jin acetate filter) to remove precipitated material which
could contribute to background autofluorescence.

An

appropriate volume of extract or doxorubicin solution was

added to sterile filtered {0.2 |am acetate filter) incomplete
media, to achieve 5% v/v Chara extract or 5nM Doxorubicin.
The addition of FBS and antibiotic resulted in final desired

concentration of all media components.

Control media was

prepared with sterile water.

D. Cellular Proliferation

An inoculum of 2ml containing 4 X 10^ cells/ml of Jensen
sarcoma or 5 X 10^ cells/ml of non-cancerous cell lines was
applied per well in 6-well (34.6mm diameter) polystyrene
culture plates . Cells were harvested every 24 hrs after

plating by exposure to 0.25% trypsin and ImM EDTA at ST^C for
about 5 min, followed by centrifugation at 2,000g for 5 min.
Cell pellets were resuspended in 1 ml of media containing
0.4% trypan blue (Sigma).

The number of viable cells were

then counted using a hemocytometer.

Additionally, cells were

enumerated by visual inspection within the cell cultures.

This was done by adding trypan blue to cultures and counting
the cells under a Nikon inverted microscope using an occular
grid calibrated using a micrometer.

E. Immunological Techniques

Except where indicated, all immunological techniques

were based on methods outlined in The American Society for

Cell Biology Education Committee Workshop (1992). Nunc 4
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chamber tissue culture slides were inoculated with 0.7 ml per

chamber of previously mentioned cell densities.

Sample

slides were taken at 24 hr intervals after treatment for the

duration of each experiment.



Slides were washed with lOiriM phosphate buffered saline
(PBS) at pH 7.4, and cells were fixed with 2% EM-grade
formaldehyde/PBS for 20 min at room temperature (RT). After
washing 3 X 10 min with PBS, the sarrple slides were stored at
40G in PBS.

Cells were permeabilized with 0.25% Triton X-100

for 5 min at RT followed by a PBS wa.sh. The slides were then
incuba.ted for 1 hr at 37^0 in a humidified chamber, with 50|Xl

human antibody (AK) to PCNA (Andrade et al., 1993) or doublelabeled with rabbit antibody (R288) to p80 coilin (Andrade et
al., 1993) and mouse monoclonal antibody (72B9) to
fibrillarin (Reimer et al., 1987) at 1:200 dilution.

All

primary antibodies were generously donated by Dr. Robert L.
Ochs, W.M. Keck Autoimmune Disease Center, The Scripps
Research Institute, LaJolla, CA.

Slides were washed 3 X 10

min with PBS at room temperature (RT) and rinsed prior to

addition of 200|J.L of appropriate secondary antibodies linked
to FITC or rhodamine (Vector,). Samples were incubated under
the same conditions as the primary antibodies. Slides were

then again washed with PBS fpllowed by double-distilled
water.

Coyerslips were mounted using Pluorsave

(Calbiochemical, La Jolla, CA) to minimize quenching of the
fluorescence signal.

Specimens were examined under 400X with a Nikon Optiphot
microscope equipped with phaSe contrast optics and an

episcopic-fluorescence attachment EF-D, containing excitatipn
filters B2A at 495nM for FiTC and G2A at 546nM for rhodamine.

Cells were photographed with a UFX-II camera system using
Ektachroine 400 or Fujichrome 100 slidefilm.

Coiled bodies

were quantified directly from 35mm slides examined at
constant magnification in a slide projector.
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PCNA stained

nuclei were scored on the basis of iitimunofluorescence

patterns as outlined in Bravo (1986) and Bravo and MacDonald
Bravo(1985).

F. Western Blotting

Samples were prepared by inoculating 2bcvc? culture
flasks withS mL of cell suspension. After plating, cells were
harvested every 48 hrs by treatment with 0.25% trypsin and
ImM EDTA at 31'^C for 5 min.

Culture media and FBS containing

2mM phenylmethylsulfonyl fluoride (PMSF) was then added and
the preparation was centrifuged 2,000g for 5min.

Cell

pellets were resuspended and centrifuged in culture media
containing ImM PMSF, twice.

Each pellet was resuspended with

an equal volume of PBS and treatment buffer (0.125M Tris-Cl
pH 6.8, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol) to

attain a concentration of 2 X 10^ cells/fil as determined from
hemocytometer counts.

Molecular weight markers were treated

the same way.

Cells were subsequently lysed by drawing the sample in
and out of a Hamilton syringe prior to heating at 95°C for 5
min followed by storage at -20°C.

Samples were thawed and

heated at 950C for 5 minutes prior to loading 10|1L of sample
on a discontinuous polyacrylamide gel containing 0.1% SDS
(Laemmli, 1970), with the following proteins for molecular
weight comparison:

bovine albumin (66Kd), egg albumin

(45Kd), glyceraldehyde 3-phosphate dehydrogenase (36Kd), and

carbonic anhydrase (29Kd).

A 5% stacking gel and 10%

separating gel were used in a Bio-Rad mini-protein II

vertical gel apparatus.

Electrophoresis was performed with a

0.025 M tris, 0.192 M glycine and 0.1% SDS pH 8.3 buffer at
15mA> set to constant current for 90 min at room temperature

(RT) using a Savant Instrument Inc. power supply model
CVR300.
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After electrophoresis, the gels and 0.2|ain nitrocellulose
paper (S&S NC) were prepared for electrotransfer by soaking
in Towbin transfer buffer for 30 min. Proteins were
transferred to nitrocellulose membranes in a Bio-^Rad mini-

trans blot system at SOV/gel under constant current for 2 hr
at 4bc. The transfer buffer was continuously mixed with a
magnetic stirrer.

Following protein transfer the nitrocellulose membranes
were stained with 0.5% Ponceau S stain for 30 seconds and
rinsed in water to determine the eveness of the transfer.

The nitrocellulose membranes were destained by rinsing in

PBS.

The gels were stained 3 hr with 0.125% coomassie blue

R-250, 50% methanol, 10% acetic acid and destained 1 hr with

50% methanol, 10% acetic acid followed by 7% acetic acid and

5% methanol until the background was clear.

Nitrocellulose

membranes were prepared for immunoblotting by blocking
membranes with 5% non-fat milk in lOOmM tris buffered saline

(M-TBS) at pH 7.5 for 1 hr at RT.

Membranes were incubated

for 1 hr at 1/200 dilution in M-TBS of human antibody Shiptak
against p80-coilin with gentle aggitation.

Membranes were

washed 3 X 30 minutes in M-TBS, then incubated with

biotinylated anti-human antibody at 1:1000 dilution in M-TBS
for 1 hr at RT.

Membranes were then washed 3 X 10 minutes in

tris buffered saline at pH 7.5 (TBS) followed by incubation
of avidin-HRP at 1:1000 dilution in TBS for 1 hour.

After

washing 3 X 10 minutes in TBS, membranes were colorized with

4-chloro-l-napthol followed by rinsing in TBS followed by
double-distilled water.

Immunoblots were digitized and

relative optical densities obtained using an IS 1000 Digital
Imaging system (Alpha Innotech Corporation) at Loma Linda
University.
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RESULTS

Preparation of Chara Extract

Previous methods for the preparation of a Chara extract
involved collection of steam distillates derived from the

alga.

For this study, a new method was employed for the

preparation of the extract.

This involved direct extraction

of soluble agents from the alga using a juice extractor,

followed by filtration with 0.2|am acetate filter.
The final extract exhibited a light yellowish/green
color.

Addition of 5% v/v of the Chara extract did not

appear to affect the pH of the culture media, since no
apparent change was observed with the phenol red indicator.

Effect of Agents on Cell Proliferation

Prior to treatment with anti-growth agents, the growth
kinetics of untreated cell lines were examined to establish a

control base line (figure 2).

Jensen sarcoma exhibited a lag

period of 24 hrs following plating, prior to a noticeable

increase in cell density.

Other cells lines exhibited

noticeable proliferation within the same time period.
The cell density of the various lines after 7 days in culture

varied significantly.

Jensen sarcoma reached a peak density

of about 6.5 X 10® cells/well, while Intestine 407 and Chang
liver attained a density 3.5 X 10® cells/well and 2.1 XIO®
cells/well, respectively (figure 2).
The addition of 5nM doxorubicin or 5% v/v Chara extract

to the three cell lines markedly affected their growth
kinetics (figure 2).

With Jensen sarcoma, treatment with

Chara extract resulted in a significant decrease in cell

density after 24 hr, while doxorubicin produced a significant
decrease in cell density, relative to controls, only 48 hrs
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after treatment.

There were no significant

differences between Chara extract and doxorubicin treated

cells at each time point.

Compared to Jensen sarcoma, Chang

liver and Intestine 407 responded quite differently to
treatment with Chara extract and doxorubicin.

First, both

,cell lihes exhibited significant reaction to Chara treatment

only in the plateau growth phase, when measurable difference
in density were evident between 120 and 144 hrs for Intestine
407 and 96-144 hrs for Chang liver.

Interestingly,

doxorxibicin significantly affected Intestine 407 cells after
24 hrs relative to both controls and Chara treated cultures.

Assessment of the growth kinetics by microscopy, shows a

similar behavior as seen with the hemocytometer counts

(Figure 3).

This method of cell enumeration did, however,

result in a lower total cell count per well compared to the
hemocytometer method.

This could be accounted for by the

knowledge that in small cultures, such as 6-well plates,
cells cluster at the edges of the wells.

If samples are not

taken in such areas of the well, the cell density would be
underestimated.

Morphological Changes

Jensen sarcoma cells normally exhibited a spindle shaped

morphology during inteirphase (figure 4).

However 72 hrs

after treatment with either Chara extract or doxorubicin,
marked morphological changes were evident.

The cells now

exhibited hyperplasia along with long cytoplasmic extensions
(figure 4)

In contrast, the cytoplasmic borders of the non

cancerous cell lines appeared flattened and round.

Treatment

with either doxorubicin or Chara did not appear to result in
an altered morphology (figure 4).
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Figure 2. Logarithmic growth Gurves of Jensen sarcoma.
Intestine 407 and Chang liver cells as assessed by trypan
blue exclusion following dissassociation with trypsin and
EDTA. Iriitial platirig densities are indicated at (P) time
period. While initial exposure to Chara extract and
doxorubicin are indicated by (T). Culture medium was
replaced every 48 hrs. Significant differences as assessed
by Diincan's multiple range test (P<0.05) are indicated as (#)
for untreated versus Chara treated. (*) for doxorubicin
treated versus untreated and (+) for Chara versus doxorubicin

treated cells.

Data represent the meaii ± SE of 3 independent

experiments performed in;triplicate.
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Figure 3. Logarithmic growth curves of Jensen sarcoma,
Intestine 407 and Chang liver cells as assessed by trypan
blue exclusion. Initial plating densities are indicated at
(P) time period, while initial exposure to Chara extract and
doxoriibicin are indicated by (T). Culture medium was
replaced every 48 hrs. Significant differences as assessed
by Duncan's multiple range test (pcO.OS) are indicated as (#)
for untreated versus Chara treated, (*) for doxorubicin
treated versus untreated and (+) for Chara versus doxoriibicin

treated cells.
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Figure 4.

Phase contrast photomicrographs of control, Chara

extract and doxorubicin treated cells from Jensen sarcoma.

Intestine 407 and Chang liver cells.
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Magnification 1500X.
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Effects of Agents on Nuclear Indicators

As outlined in the introduction, the nuclear protein

fibrillarin is present in nucleoli, certain peri-nucleolar
structures and coiled bodies (CBs).

However, preliminary

studies by Brasch et. al., (1994), using double labeling with
mouse monoclonal antibody (72B9) to fibrillarin and rabbit
antibody (R288) to p80-coilin, revealed significantly less
than 100% coincident labeling of GBs by the two antibodies.

Although all CBs appeared p80-coilin positive, not all were
also fibrillarin positive, suggesting that two overlapping

populations were present, at least operationally.
To investigate this possibility further and to avoid
ambiquity in identifying and quantifying fibrillarin and
coilin-containing strucutres, data from each antibody were
first analyzed independently.

A. Fibrillarin

Immunofluorescence localization of fibrillarin

containing structures in Jensen sarcoma. Intestine 407 and

Chang liver cells by the anti-fibrillarin antibody 72B9 is
shown in figure 5.

Comparison of phase contrast and

fluorescent images of the same cells (data not shown)
revealed that the most prominent labeled regions coincided
with nucleoli while CBs and other smaller labeled structures

appeared throughout the interchromatin domain.
This pattern of fibrillarin-specific labeling has been

widely reported in many other cells and tissues and is
thought to represent primarily pre-nucleolar bodies and
elements associated with RNA processing (Spector, 1993).

Despite the relatively small fluctuations with respect to
treatment and time (figure 6 and table 1), fibrillarin
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Figure 5. Photomicrographs of control, Chara extract and
doxorubicin treated cells from Jensen sarcoma, Intestine 407
and Chang liver cells labeled with mouse monoclonal antibody
72B9 against the nuclear protein fibrillarin. Nuclear
structures labeled with anti-fibrillarin antibody are
indicated by arrows. Magnification 1500X.
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Figure 6. Quantitation of fibrillarin containing nuclear
structures in Jensen sarcoma. Intestine 407 and Chang liver.

Bars with an (*) above indicate significant differences
between treatment groups within each time frame as assessed
by Duncan's multiple range test (P<0.05). Data represents
the mean ± SE Of 100-250 cells.
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Average Number of Fibrillarin Labeled Structures/Nucleus

Table 1. Pairwise comparison of the influence of time on the
average number of fibrillarin labeled structures for each
cell tvpe within control. Chara and doxorubicin.

Time

Group (Hrs)
Con

24

Con

48

Con

72

Con

96

Chara

24

Chara

48

Chara

72

Chara

96

Doxo

24

Doxo

48

Doxo

72

Doxo

96

Jensen

Intestine

Chang

Sarcoma

407

liver

48

72

96

120

48

72

96

120

48

72

96

120

S

S

S

S

S

NS

NS

NS

NS

S

NS

NS

NS

NS

NS

NS

S

S

S
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NS

NS

NS

NS

S

S

S

-

-

-
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-
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-
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NS
-

-

-

-

,S
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S
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-

-

S
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-

-

-
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S

S
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s

S
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S

-■

S

-

NS

Calculated using Duncan's multiple range test. Significant
differences (P<0.05) between paired time points are indicated
by (S) , while non-significant comparisons are indicated by
(NS) .
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distribution patterns were surprisingly unifonn and similar

in all three cell types.

Nuclei in control Jensen sarcoma

Cells, typically exhibited one (or more) large fibrillarin
rich nucleolar regions as well as smaller peripheral

structures and usually one distinct CB adjacent to the
nucleolus or within the interchromatin region.

Similar

fibrillarin distribution was evident in Chara and doxorubicin

treated Jensen sarcoma, however the periphery of the
nucleolus appeared less irregular (figure 5).

In the non

cancerous cells, fibrillarin containing structures appeared
smaller and more numerous than those observed in Jensen

sarcoma (figure 5 and 6).
B. Coiled Bodies

As outlined in the introduction, in addition to several

molecules associated with pre-mRNA and rRNA processing,
coiled bodies are characterized by at least one luiique
protein, p80-coilin.

Immunofluorescence localization of CBs

by the anti-p80-coilin antibody R288 in Jensen sarcoma.
Intestine 407 and Chang liver is shown in figure 7.
Quantitative analysis of CBs identified by R288 revealed
marked changes, not only with respect to cell type, but also

in relation to time and treatment regime (figure 8 and table
2).

This was particularly dramatic in Jensen sarcoma.

Initially at 24 hrs, under all treatment conditions, an
average of 0.19 ± 0.05 or less CBs per nucleus was observed
in Jensen sarcoma cells.

In control cells this value rose

progressively thereafter and by 72 hrs effectively all nuclei
contained at least 0.96 ±0.08 CB on average.

This was

followed by a gradual decline and at confluency, an average
of 0.67 ± 0.07 CBs per nucleus was the norm.

A. significantly different pattern emerged in Jensen
sarcoma treated with Chara extract or doxorubicin.
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Figure 7. Photomicrographs of control, Chara extract and
doxorubicin treated cells from Jensen sarcoma, Intestine 407

and Chang liver cells labeled with rabbit antibody R288
against the protein p80-coilin. p80-coilin labeled
structures are indicated by arrows. Magnification 1500X.
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Figure 8.

Quantitation of pBO-coilin containing coiled

bodies in Jensen sarcoma, Intestine 407 and Chang liver.
Bars with an (*) indicate significant differences between
treatment groups within each time frame as assessed by
Duncan's multiple range test (P<0.05). Data represents the
mean ± SE of 100-250 cells.
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Table 2. Paiirwise comparison, of the influence of time on the
average number of p80-coilin containing structures for each
cell type within control, Ghara and doxorubicin.

Time ^

Group (Hrs)

Con

48

Con :

72

Con

Chara

.

Intestine

Chang

407

liver

48

72

96.
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48

72

96

120

48
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S

S

S

S

S
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NS

S
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S
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NS
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NS
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.

-
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24
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■
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-
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S
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s
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-

NS

■
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S
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s
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S

s

s
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S

-
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-

S

Galculated using Duncan's multiple range test. Significant
differences (P<0.05) between paired time points are indicated
by (S), while non-significant corrparisons are indicated by
(isrs)
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Both agents had a significant inhibitory effect on CB

development, which was particularly strong with doxorubicin.

With both agents, the average number of GBs never exceeded
0.57 ± 0.06 and indeed with doxorubicin, never eixceeded 0.41
± 0.07 CBs per nuclei.

A significantly more mixed pattern of CB development was
evident in Intestine 407 cells (figure 8).

Under control

conditions, the average fluctuated between 1.41 ± 0.08 and

2.11+0.10 CBs per nucleus for the duration of the culture.
The presence of Chara extract or doxorubicin did have a

generally negative effect on CBs average over time, but this
appeared far more varied than in Jensen sarcoma (figure 8 and
table 2).

Control Chang liver cells averaged the largest number of
CBs per nucleus of all three cell lines ranging around 2.45 ±
0.12 to 3.21 ± 0.16 CBs per nuclei (figure 8).

A slow but

significant decrease in these values was evident over time,
an effect that was enhanced in the presence of Chara extract.
Remarkably, however, even at confluence the niomber of CBs

still averaged around 2 in this cell line.

C. Coiled Body Subpopulation

As previously mentioned, although all identifiable CBs
were labeled by antibodies against p80-coilin, not all those

bodies were recognized by the anti-fibrillarin antibody 72B9.
Quantitative analysis of these two CB populations revealed

major differences with respect to cell type, time and ahti
neoplastic treatment (figure 9,10,11 and tables 3,4,5).
In Jensen sarcoma, the average number of fibrillarin
positive and negative CBs at 24 hrs was less than 0.2/nucleus
under all treatment conditions.

In control Jensen sarcoma

the number of fibrillarin positive CBs rose significantly

thereafter peaking at 72 hrs with a gradual decline at

41

Figure 9. Quantitation of coiled body subpopulation in
Jensen sarcoma. Fibrillarin positive CBs, fibrillarin
negative CBs and and percentage of total CBs positive for :
fibrillarin. Bars with an (*) indicate significant
differences between treatment groups within each time frame
as assessed by Duncan's multiple range test (P<0.05). Data
represents the mean ± SE of 100-250 cells.
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Table 3.

Pairwise comparison of the influence of time in

Jensen sarcoma within control, Chara extract and doxorubicin
treated cells for number of fibrillarin positive and

negative, p80-coilin containing structures along with % total
fibrillarin positive CBs.
Fibrillarin

Fibrillarin

% Total

Positive

Negative

Fibrillarin

Time

Con

24 :

Con

48

Con

72

Con

96 :

Chara

24

Chara,

48

Chara

72

Chara

96

Doxo

24

Doxo

48

Doxo

72

Doxo

96

■

48
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S ^
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-
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■
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■
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-
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■• ■V s ■
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S
NS
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-r

:V " S
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s

-

s

Positive CBs

CBs

CBs

Group (Hrs)

NS

NS

Calculated using Duncan's multiple range test.
differences (P<0.05) between paired time points are indicated
by (S), while non-significant comparisons are indicated by
(NS) .
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Figure 10.

Quantitation of coiled body subpopulation in

Intestine 407.

CBs labeled with fibrillarin, CBs with no

labeling for fibrillarin, and percentage of CBs labeled with
fibrillarin. Bars with an (*) indicate significant
differences between treatment groups within each time frame
as assessed by Duncan's multiple range test (P<0.05). Data
represents the mean ± SE of 100-250 cells.
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Table 4.

Pairwise comparison of the influence of time in

Intestine 407 within control, Chara extract and doxorubicin
treated cells for number of fibrillarin positive and

negative, p80-coilin containing structures along with % total
fibrillarin positive CBs.
Fibrillarin

Fibrillarin

% Total

Positive

Negative

Fibrillarin

Con

24

Con

48

Con

72

Con

96

Chara

24

Chara

48

Chara

72

Chara

96

Doxo
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Doxo
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S
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-
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-
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-
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-
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-
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-
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-
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-
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-
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-
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-
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Calculated using Duncan's multiple range test. Significant
differences (P<0.05) between paired time points are indicated
by (S), while non-significant comparisons are indicated by
(NS).
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Figure 11. Quantitation of coiled body subpopulation in
Chang liver. CBs labeled with fibrillarin, CBS with no
labeling for fibrillarin, and percentage of CBs with
fibrillarin labeling. Bars with an (*) indicate significant
differences between treatment groups within each time frame
as assessed by Duncan's multiple range test (P<0.05). Data
represents the mean ± SE of 100-250 cells.
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Table 5. Pairwise comparison of the influence of time in
Chang liver within control and Chara extract treated cells
for number of fibrillarin positive and negative, p80-coilin

containing structures along with % total fibrillarin positive
CBs.- ■ '■ ■ ■ ■
Fibrillarin

Fibrillarin

% Total

Positive

Negative

Fibrillarin

Time

Group
Con .

CBs

Positive CBs

CBs

(Hrs)
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72

96
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72
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S

S

S
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S

S

S
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Chara

48

Chara

72

Chara

96

-

S
-

-
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-
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differences (P<0.05) between paired time points are indicated
by (S) , while non-significant comparisons are indicated by
(NS) .
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confluency, while fibrillarin negative CBS reitiained constant
after an increase at 48 hrs (figure 9).
Treatment with either Chara extract or doxorubicin

appeared to have inhibitory effects on development in both
fibrillarin positive and negative CBs (figure 9).

The

effects of doxorubicin was particularly strong on both

fibrillarin positive and negative CBs. while Chara's
inhibitory effects appeared stronger on fibrillarin negative
CBs as compared to those labeled with fibrillarin.
Even with the observed inhibitory effects of both Chara
and doxorubicin on fibrillarin positive and negative CBs, the
relative proportions of these two types of CBs appears to be
relatively unchanged compared to control JenSen sarcoma

except for a significant increase in fibrillarin positive
CB's at 24 hrs treated with doxorvibicin (figure 9).

In control Intestine 407 cells (figure 10), the pattern
of development for fibrillarin positive CBs was mixed over

time, while fibrillarin negative CBs remained fairly
constant.

Addition of either Chara extract or doxorubicin

produced mixed effects on both CB types with respect to time.
However, assesment of the relative proportions of fibrillarin

positive and negative CBs remains constant between control
and doxorubicin treated cells, while Chara treated cells

exhibited a higher proportion of fibrillarin positive CBs
early on.

For both control and Chara treated Chang Liver (figure
11), the appearance of fibrillarin positive and the
proportion of fibrillarin positive CBs appeared to increase

with age in culture, while fibrillarin negative CBs appeared
to decrease with age in culture.

Treatment with Chara

extract appeared to have only very modest inhibitory effects
on both fibrillarin positive and negative CB development.
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D. Western Blot Analysis

P80-coilin has

examined so far.

been detected in all vertebrate cells

In the present study, western blotting

analysis of SDS-PAGE separated polypeptides from all 3 cell
lines was undertaken for two reasons.

First, it was

necessary to establish and confirm that p80-coilin was

present in these cells.

Second, it was necessary to validate

independently the prescence of this protein with respect to
the immxmofluorescence analysis of CBs.
The human antibody against p80-coilin (shiptak),
identified a single band in western blots of SDS^PAGE

separated proteins in all three cell lines (figure 12).
Moreover, this single band was evident under all treatments

and time points examined as assessed by densitometric
analysis (table 6).
The densitometric analysis also suggested that
considerable quantitative differences in p80 content were

manifest not only among the three cells lines but also under
various treatment/growth conditions.

This would have to be

verified, however, by repeat experiments and more rigorous
statistical analysis.

E. PCNA Quantification

As described in the introduction, proliferating cell

nuclear antigen (PCNA) can be used as an indicator of the
replicative status of cells.

In this study three major

labeling patterns were observed with human antibody AK
against PCNA (figure 13):

a) homogeneous labeling of the

entire nucleus, b) granular labeling throughout the nucleus,
and c) labeling of the nucleus excluding nucleolar regions.

These patterns were operationally termed homogenous, granular
and nucleolus-negative respectively.

52

Figure 12. Western blot using the hioman antibody Shiptak
against p80-coilin in Jensen sarcoma, Intestine 407 and Chang
liver. Control, Chara extract and doxorubicin treated cells
were examined, following 24, 72, and 120 hrs after treatment.
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Table 6. Relative optical densities in western blot of p80
coilin using the human antibody Shiptak.
Group
- CONTROL

Time (Hrs)

Jensen sarcoma

24

Intestine 407

Chang liver

0.75

0.92

CHARA

24

0.73

0.81

0.94

DOX

24

0.87

0.73

-

0.94

0.77

0.87

0.92

0.59

0.96

0.96

1.00

CONTROL

72

CHARA

72

DOX

72

CONTROL

120

0.99

1.00 ,

CHARA

120

1.00

0.74

0.99

DOX

120

0.74

0.82

;

-

-

Relative O.D. values were derived
using the IS 1000 Digital
O
MC
Imaging system by integrating00 the density area from each
band. ,

o
O
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Figure 13.

Photomicrographs of hxjman antibody AK against

PCNA in untreated and treated Jensen sarcoma. Intestine 407

and Chang liver. The various PCNA labeling patterns observed
within the cells are denoted by homogenous (a), granular (b)
and no nucleolar labeling (c). Magnification at 1500X.
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The nucleolus-negative patterns are characteristic of cells
in late G1 and entering early S-phase, while granular

appearing cells are in active S-phase proceeding to G2 phase

and homogenous labeling patterns correspond to the remaining
portions of interphase

(Bravo and Macdonald-Bravo, 1985).

The assesments of PCNA labeling for all times and
treatment conditions in Jensen sarcoma are summarized in

figure 14 and table 7.

It is noteworthy that, overall, over

50% of the cells under all treatment conditions exhibited

nucleolus-negative staining patterns.

This corresponds to

the late G1 and early S phase transition (Bravo and
Macdonald-Bravo, 1985) and remained fairly constant over
time.

In contrast, granular (active S-phase) and homogenous

(G1 and G2 phase) labeling patterns varied significantly in
control cultures.

granular patterns.

At 24 hrs, about 5% of cells showed

This rose to over 15% at 72 hrs and

gradually declined as the cultures reached confluency.
Homogenous labeling was highest (~ 35%) at 24 hrs and at

confluency, with lower values in between.
Unlike Jensen sarcoma, intestine 407 cells exhibited
predominantly (50-70%) homogenous (Gl and G2) labeling ;
patterns at all times and under all treatment conditions

(figure 15 and table 8).

Nuc1eo1ar-negative (Gl^ S) labeling

was evident in less than 30% of cells at all times.except
confluency, when nearly 50% of cells shared that pattern.

Relative to both Jensen sarcoma aind intestine 407, Chang
liver displayed a more even proportion of cells with either
homogenous (Gl and G2) or nuc1eolus-negative (Gl^ S) labeling

under the two treatment conditions examined (figure 16 and
table 9).

Despite the initial gradual decline in granular

labeled cells in Chang liver no statistical differences were

observed over time with respect to both treatment conditions
(table 9).
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Figure 14. Quantitation of PCNA labeling in Jensen sarcoma.
Percentage of cells labeled with an absence of the nucleolar

region, percentage of cells exhibiting granular staining
including the nucleolus, and percentage of cells exhibiting
homogenous labeling. Bars with an (*) indicate significant
differences between treatment groups within each time frame
as assessed by Duncan's multiple range test (P<0.05). Data
represents the weighted mean ± SE of 3-8 separate fields
comprising 100-250 cells.
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Table 7.

Pairwise comparison of the influence of time in

Jensen sarcoma within control, Chara extract and doxorubicin
treated cells for number of nucleolus-negative, granular and
homogenous labeled cells.

Negative

Time

Group (Hrs)

Homogenous

Granular

Nucleolus

48
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96
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NS

S

S

S
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-
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Calculated using Duncan's multiple range test. Significant
differences (P<0.05) between paired points are indicated by
(S), while non-significant cortparisons are indicated by (NS)
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Figure 15.

Quantitation of PCNA labeling in Intestine 407.

Percentage of cells labeling with an absence of the nucleolar
region, percentage of cells exhibiting granular labeling
including the nucleolus, and percentage of cells exhibiting
homogenous labeling. Bars with an (*) indicate significant
differences between treatment groups within each time frame
as assessed by Duncan's multiple range test (P<0.05). Data
represents the weighted mean ± SE of 3-8 separate fields
corrprising 100-250 cells.
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Table 8. Pairwise comparison of the influence of time in
Intestine 407 within control. Chara extract and doxorubiciri
treated cells for number of nucleolus-negative, granular and
homogenous labeled cells.
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Time

Group (Hrs)
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Figure 16.

Quantitation of PCNA labeling in Chang liver.

Percentage of cells labeling with an absence of the nucleplor
region, percentage of cells exhibiting granular labeling
including the nucleolus, and percentage of cells exhibiting
homogenous labeling. Bars with an (*) indicate significant
differences between treatment groups within each time frame
as assessed by Duncan's multiple range test (P<0.05). Data
represents the weighted mean ± SE of 3-8 separate fields
comprising 100-250 cells.
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The application of Chara extract seemed to affect the overall

pattern of PCNA labeling most strongly in Jensen sarcoma
(figure 14 and table 7).

This was particularly pronounced

with respect to granular (active S-phase) labeling where the

extract had a significant inhibitory effect relative to both
control and doxorubicin treated cultures.Somewhat

surprisingly, doxorubicin seemed to have a mild stimulating
effect in Jensen sarcoma with regard to granular labeling,

although this pattern was not uniform over time.
Despite some apparently significant differences with
respect treatment or time factors no consistent trends were
evident for controls, Chara extract or doxorubicin treatment
in Intestine 407 or Chang liver.

Indeed. Chara extract had

virtually no effect on PCNA labling in Chang liver and very
little in Intestine 407 compared to controls.
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DISCUSSION

The primary focus of this investigation was to further
examine the effects of an extract from the alga Chara

alobularis on the growth of cancerous and non-cancerous cells
in culture.

The approach taken was to corrpare the effects of

such extracts relative to those of the well characterized

anti-neoplastic agent, doxorubicin.

Several cell cycle and

transcription-related indicators were monitored for this
purpose, including cell morphology, growth kinetics, the
appearance of coiled bodies, nucleoli and PCNA labeling.

These parameters were examined in relation to cell type, time
in culture and treatment with anti-neoplastic agents.

Cell Proliferation and Morphology

The results of the present investigation clearly
demonstrated that addition of 5% v/v Chara extract markedly
inhibited the growth of Jensen sarcoma cells in culture.

Indeed, the extract appeared to be both more effective and
selective in this regard than 5nM doxorubicin.
For example, not only was inhibition of Jensen sarcoma by

Chara extract faster than doxorubicin (24 vs 48 hrs after
treatment), it was also less pronounced than doxorubicin in
the non-cancerous, intestine 407 cells.

Collectively,

therefore, these results strongly support previous reports
(Gallo, personal communication; Sherif, 1980) that the alga

Ghara contains coirpounds with anti-neoplastic properties
Application of Chara extract did significantly affect
cell density at the plateau phase in the two non-cancerous
cell lines, though far less dramatically than Jensen sarcoma.

This may well reflect cytotoxic activity resulting from
accumulation of extract-derived, secondary metabolites that
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only reached critical concentrations as the cultures

approached confluence (Dolfini et al,

1973).

Vtoile Chara extracts appeared to preferentially inhibit
growth of Jensen sarcoma, doxorubicin inhibited the growth of
both Jensen sarcoma and Intestine 407.

This observed action

by doxorubicin on both cancerous and non-cancerous cells has
also been reported in other studies (Tidefelt et al.,.1991).

Although the precise reason for this is unclear, doxorubicin
may have a broad spectrum inhibitory action on cell growth
compared to Chara extract.

Unlike the non-cancerous cells which did not exhibit any
gross alterations in morphology following prolonged treatment
with either Chara extract or doxorubicin, Jensen sarcoma

cells exhibited hyperplasia along with an increase in
cytoplasmic extensions.

Such gross changes in morphology in

cancerous cells may be a prelude to eventual resistance
against anti-neoplastic agents, through induced
differentiation at the nuclear, cytoplasmic, or membrane
levels.

There are niomerous reports in the literature that cancer
cells resistant to anti-neoplastic agents exhibit one or more

of the following characteristics:

a) differentiated

morphology due to changes in expression of adhesion and

membrane proteins, b) increased expression of P-glycoprotein
which is involved in the efflux of drugs from the
intracellular region, c) slower rates of growth, and d)

increased expression Of enzymes involved in the metabolism of
anti-neoplastic agents such as glutathione-S-transferase

(Gibelli et al., 1994; Rasbridge et al., 1994; Choa et al.,
1992).

Agents have also been found that can redirect

cellular differentiation by binding to actin and inducing

polymerization or stabilization of pre-existing actin
filaments (Bubb et al., 1994).

Amine oxides reportedly

induce changes in molecular organization, osmotic and
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permeabilitY characteristics of cell membranes (Miko and
Devinsky 1992), and retinoids have been found to modulate

gene expression by binding to RAR chromosome sites (Pemrick
et al., 1994).

Fibrillarin Containing Structures

Despite significant changes in CB frequency and PCNA
staining patterns (see discussion below), nucleolar

components as revealed by immunfluorescence labeling with
anti-fibrillarin antibody 72B9, remained comparatively
stable.

This overall uniformity was evident among all three

cell lines, both in terms of treatment regime and age in

cultures.

Since fibrillarin is a major structural protein of

pre-nucleolar bodies and nucleoli (Oches et al., 1985;

Spector, 1993) these observations indicate that the
structural integrity of these key nuclear domains was
relatively unaffected by the diverse growth and treatment
conditions utilized in this investigation.

However, it

remains unclear whether such stability also expanded to the
functional aspects of these domains, namely rRNA metabolism

and pre-ribosome production.

Any nijmerical and morphological assesment of fibrillarin
containing nuclear structures based on light microscopy is

clearly limited in resolution and should be extended to the
electron microscope level.

Moreover, inclusion of all

fibrillarin positive elements in this analysis (pre-nucleolar

bodies, nucleoli, GBs and other smaller components), could
well mask time and/or treatment effects on each individual

structure.

That was certainly the case with respect to

fibrillarin negative CBs (see discussion belpw), but it is
also known that the size and shape of nucleoli vary with

respect to the cell-cycle.

During Gl, nucleoli are

characterized as small segregate structures possibly
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coalescing into larger more prominent nucleoli during G2
(Spector, 1993).

Such effects may not have been as

pronounced in the present study which utilized asynchronous
cells.

In the present study, the apparent absence of major
structural effects on fibrillarin containing nuclear
structures in terms of treatmient could indicate that rRNA

transcription was insensitive to the concentrations of Chara

extract or doxorubicin employed.

For example,

immunofluorescent labeling of cells treated with the

transcriptional inhibitors, actinomycin D or 5,6-dichloro-l

beta-d-ribo furanosyl benzimidazole which selectively block
rRNA production, induced segregation of nucleoli into remnant
structures (Raska et al, 1990),

observed here.

That was clearly not

Along related lines, while RNA polymerase II

and III have been shown to be sensitive to doxorubicin

treatment (Chaung and Chuang, 1979 and Logan and Ackerman,
1988), RNA polymerase I, which is responsible for rRNA
transcription, appears to be insentive to this agent at
micromolar concentrations (Wassermann et al, 1988).

Nonetheless, doxorubicin can induce nucleolar segregation at
relatively high micromolar concentrations (Abe et al, 1996),
indicating that its precise mode of action in this regard
remains to be determined.

Coiled Bodies and Cell-Cyde

The results of the present investigation are in general

accord with many previous studies on cells in cultures. (For
Review:

Brasch and Ochs, 1992; Lamond and Carmo-Fonseca,

1993), showing that CB niombers can vary in relation to growth

and metabolic rates and stages of the cell-cycle.

Beyond

that, however, significant differences were observed among
the three cell lines utilized here.
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Not only were the

absolute niiiribers of CBs different, lowest in Jensen sarcoma

and highest in Chang liver, but their relative frequency over;
time also varied significantly.

For example, in Jensen

sarcoma control cultures, only an average of two cells in ten
displayed CBs at 24 hrs, while at 72-96 hrs virtually all
cells did.

In sharp contrast, Chang liver averaged 2.4-3.2

CBs for the duration and intestine 407 values were

intermediate.

Since the accompanying western blot data did

not reveal comparable quantitative differences in total cell
p80-coilin levels, the observed differences in both absolute
and relative CB numbers must be due to, as yet, unknown
causes.

a

'v

■

An unexpected and potentially very interesting
correlation emerged when CB nxjmber changes and PCNA labeling
patterns were compared.

For all three control cultures, the

pattern of CB development over time, appeared to parallel
most closely the development of nuclei exhibiting granular
labeling which corresponds to those active in DNA synthesis
(Bravo and Macdonal-Bravo,1985).

This does not imply that

more CBs developed during S-phase compared to either G1 or
G2, since this study utilized asynchronous cultures.
Actually the opposite is observed in synchronous cultures
where cells in S-phase exhibit the fewest CBs compared to G1
or G2 (Andrade et al, 1991).
The addition of Chara extract to the non-cancerous cells

did appear to depress CB development slightly, particularly
in Chang liver during periods of logarithmic growth and near
plateau, while not altering the relative proportion of

various PCNA labeling patterns compared to controls.

This

suggests that Chara extract did slightly modify the
transcriptional state of the non-cancerous cells, independent

of changes in proliferation.

The reason for these decreases

is unknown, but could reflect interference in a signal
transduction pathway regulating transcription or the
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transcriptional process itself.

For example, extracts from

wheat germ have been shown to interfere with RNA polymerase

III activity in yeast (Furter and Hall, 1991), while extracts
from Koelreutera henrvi and Polvaon\jm cusoidatxjm have been

observed to alter protein kinase activity (Chang et al.,
1996).

Alternatively, the observed depression in CB

development may not be due to the extract itself, but a
possible accumulation of secondary metabolites as mentioned
previously which may be affecting the cell density attained
by the non-cancerous cells.

While Chara extract appeared to exhibit little effect on

the cell-cycle of the non-cancerous cells, it had a dramatic
effect in Jensen sarcoma.

For example, the significant

increase of Jensen sarcoma cells exhibiting no nucleolar

labeling along with the significant decreases of cells with
granular or homogenous labeling, suggests that the extract

was blocking cells at the late Gl or early S-phase.

This

accumulation of cells exhibiting one PCNA labeling pattern

has been seen with drugs such as hydroxyurea that block Sphase initiation and this results in an increased number of
cells exhibiting no nucleolar labeling (Bravo and MacDonaldBravo, 1985).

Thus, the decreases seen in CB numbers in

Chara treated Jensen sarcoma corrpared to controls, may be a

reflection of a decreased rate of proliferation, as assessed
by a decrease in the proportion of cells exhibiting granular
labeling.

However, other effects of Chara extract on

transcription, such as those previously mentioned for the
non-cancerous cells, may also be involved.
The addition of doxorubicih resulted in dramatic

decreases in CB development in Jensen sarcoma and modest
changes in Intestine 407, while altering the appearance of
granular labeled Jensen sarcoma and slightly altering them in
intestine 407.

These decreases in CB development suggest

that doxorubicin may be interfering with the transcriptional
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process by intercalating within the major groove of DNA,
thus, inhibiting RNA polymerase (Logan et al., 1989).

However, while doxorubicin depressed CB development in Jensen
sarcoma, it appeared to increase the proportion of cells
exhibiting a granular labeling pattern compared to control
Jensen sarcoma.

Therefore, the intercalation of doxorubicin

within the DNA may also result in a delay in the progression

of DNA synthesis, for example, by inhibiting the helicase
progression (Bachur et al., 1992).

However the absence of a

decrease of homogenously labeled cells representing G1 and G2
phase, suggests that this might not be the case.

Instead

these increases in granular labeled Jensen sarcoma may be a
reflection of increased association of PCNA with DNA repair

sites due to DNA damage induced by doxorubicin (Celis and
Madison, 1986; Toschi and Bravo, 1988).

In, contrast to

Jensen sarcoma, doxorubicin treated Intestine 407 exhibited

an initial decrease in the proportion of cells in active Sphase.

In conjunction with the decrease and shift in CB

development over time, doxorubicin may also have exerted an
initial cytotoxic effect on intestine 407.

A surprising observation was that Jensen sarcoma cells
exhibited a high proportion of no nucleolar PCNA labeling,
while Intestine 407 exhibited the highest proportion of

homogenous labeling and Chang liver appeared to be fairly

evenly mixed between the homogenous and no nucleolar
labeling.

The significance for these differences is unknown,

but they may reflect changes in the stages of transformation
from normal to, cancerous cells.

The cancerous Jensen sarcoma

cells may be primed for entering DNA synthesis phase by
having cells at the late Gl and early S-phase, while the non
cancerous cells are set to maintain their status in either G2

or ,mdre likely, Gl.

These differences in the proportion of

cells exhibiting various PCNA labeling patterns could be
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explained by variations in the duration of each part of the
cell-cycle (Takahashi et al., 1995).

A major and somewhat unexpected finding in the present
study was the presence of two distinct populations of CBs,
one containing and one apparently lacking fibrillarin.

This

was revealed by double-labeling experiments using antibodies
against both p80-coilin and fibrillarin.

While it is

possible that these "fibrillarin-negative" CBs are truly
devoid of this protein, it is more likely that the

appropriate fibrillarin epitope was inaccessable to the anti
fibrillarin antibody 72B9.

Either way, this might indicate a

structural or conformational difference reflective of two

distinct CB sub-populations.

Whether this also indicates

possible functional differences between the two types of CBs,
and thereby account for their observed differences in

behavior in all cell cultures with respect to time and
treatment regime, is as yet unclear.
The association Of fibrillarin with CBs has been

reported before and has suggested a possible functional
relationship between nucleoli and CBs (Raska et al., 1990;

Raska et al., 1991; Ochs et al., 1994).

The significance of

these two possible classes of CBs is unknown, however they
may represent respective changes in nucleolar and
extranucleolar gene expression (Malatesta et al., 1994).
The addition of either doxorubicin or Chara extract had

a generally negative effect on both classes of CBs in Jensen
sarcoma. In Intestine 407, addition of Chara extract appeared

to affect CBs more negatively lacking fibrillarin, while

doxorubicin had a mixed effect.

In Chang liver, addition of

Chara extract appeared to have a more negative effect pn

fibrillarin positive cells compared to those without
detectable fibrillarin, particularly as the cells approach
confluency.
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A unique observation about the proportion of
"fibrillarin-positive" and "fibrillarin-negative" CBs was
made (figure 8,9 and 10).

For the most part, in all of the

cell lines, the proportion of these two CB subpopulations

appears to be insensitive to drug exposure with either Chara
or doxorubicin when using the concentrations employed.

This

suggests that the relative proportion of these two classes of
CBs within the mammalian nucleus may be tightly regulated.

The functional significance of the two CB subpopulations
and their apparent differences relative to treatment with
Chara extract and doxorubicin remains unclear.

Carmo-Fonseca

et al. (1992) have shown a decreased association of snRNP's
in CBs, while the assocation of fibrillarin with CBs
increases, in Hela cells treated with a-amanitin or heat

shock.

The change observed here may be similar in nature.

Additional Modes of Action for Chara extract Components

In Jensen sarcoma, Chara extracts appeared to be

altering CB niombers by influencing cell-cycle behaviors,
compared to doxorubicin which appeared to be directly potent
on CB development by inhibiting transcription.

The data from

this study suggest that Chara extract exert its action by

blocking or delaying the cells progression through late G1 or
early S-phase as assessed by PCNA labeling (Bhuyan et al.,

1972).

This observed action may be exerted by changes

related to the membrane or cytoskeleton.

In the alga Chara.

the internal space of antheridial cells become filled with

polysaccharides (Gosek and Kwiatkowska, 1993; Gosek and
Kwiatkowska, 1991).

These polysaccharides could bind to

specific membrane proteins which are e3<pressed in neoplastic
cells but expressed at a low level or not at all in non
cancerous cells.

The result would be to increase the

adhesiveness of the cells or block activiation of membrane
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bound receptors (Boyd and Read, 1988). In recent years, algal

polysaccharides have been shown to represent an important
class of products which exhibit various antitumor,

anticoagulant, antithrombotic and antiviral activity (For
review:

Wong et al., 1994; Lincoln et al., 1991).

The

action of Chara extract may be similar to that seen by
sulfated polysaccharides from Ascoohvllimi nodosum. which
block non-small-cell bronchopulmonary carcinoma in the G1
phase (Riou et al, 1996), Similarily, Chara contains
profilins which are actin binding proteins that help regulate
the polymerization of actin.

These profilins have been shown

to exhibit a high homology with plant profilins which have
been shown to bind to actin in cardiac muscle (Ruhlandt et

al., 1994), thus a potentially interfering with cytoskeletal
arrangements.

Either one of these mechanisms could cause a

decreased rate of proliferation and ,thus, a corresponding

decrease in rate of transcription resulting in a decrease in
CB development.

This is, however, assuming that only a

single agent is responsible for the observed action of Chara
on the growth of Jensen sarcoma in vitro and in vivo.

Possible additive or synergistic effects between various
agents could play a role as well.

Either way, the data do

appear to show that Chara naturally contains agents which

exhibit fairly selective growth inhibitory properties.

Conclusion

This study does show that Chara alobularis contains

conpounds which exhibit fairly selective anti-neoplastiC

activity.

The approach to assess Chara's potential anti-

neoplastic activity is unique, however, the approach does

look at two factors which are usually altered in cancer

cells, trancscription and cell-cycle.

This approach also

provided additional insight into the nature of nuclear
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organisation and how it is influenced by age in culture and

growth inhibitors.

Additional experiments are required to

fractionate the extract in order to illucidate the actual

agent(s) involved.

However, it is speculated that the active

agent in Chara globularis is a type of polysaccharide.

Such

anti-cancer agents may provide new approaches in treating
cancer, since convential means usually carry undersirable

side effects.

Polysaccharides are water soluble and easily

administered.

In addition they have not been found to induce

mutagenic or carcinogenic effects (Wagner. 1985).

Bioactive

polysaccharides from algae have also been shown to induce the
production of various anti-tumor cytokines with less severe
side effects associated with direct administration of

recombinant cytokines (Lenk et al. 1989).

Besides cytokine

production, these polysaccharides have been shown to
stimulate various immune cells as well.

Future knowledge of

the structural conformation of such compounds may also help

lead to the development of more potent and specific compounds
in the treatment of cancer.
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